Samsung Biologics Q1 2026 Results were officially released today, marking a significant milestone for the Incheon-based contract development and manufacturing organization (CDMO). The company reported a consolidated revenue of KRW 1,257.1 billion, representing a robust 25.8% increase year-over-year.
With full operations in plants at our Bio Campus I and Plant 5 ramp-up underway, we are further strengthening manufacturing readiness.
John Rim, President and CEO
Detailed Financial Performance: Samsung Biologics Q1 2026 Results
The financial data for the first quarter reflects the company’s ability to maintain high utilization rates across its massive capacity. Operating profit saw a substantial jump, reaching KRW 580.8 billion.
| Metric | Q1’26 (KRW Billion) | Q1’25 (KRW Billion) | YoY Change |
| Total Revenue | 1,257.1 | 999.5 | +25.8% |
| Operating Profit | 580.8 | 430.2 | +35.0% |
| EBITDA | 675.3 | 514.6 | +31.2% |
| Net Profit | 452.4* | 360.1* | +25.6% |
Operational Milestones and U.S. Market Entry
A core driver behind the Samsung Biologics Q1 2026 Results was the strategic acquisition of the Rockville manufacturing facility in Maryland, U.S., for USD 353 million. This move establishes the company’s first physical manufacturing footprint in the United States, bringing them closer to a major cluster of biopharmaceutical clients.
Key operational highlights include:
- Full Utilization: Plants 1 through 4 are operating at maximum capacity.
- ADC Facility Success: Completion of the first commercial-scale engineering run for Antibody-Drug Conjugates (ADCs).
- Plant 5 Progress: Construction and ramp-up remain on track to meet future demand.
Strategic Partnerships and Regulatory Excellence
Beyond the financials, the Samsung Biologics Q1 2026 Results highlight the company’s role in global health. A new partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) focuses on rapid response manufacturing, while a collaboration with Eli Lilly and Company aims to bolster the biotechnology ecosystem.
Regulatory and Service Capacity Data
The following table outlines the company’s growing clinical and regulatory footprint as of the end of Q1 2026.
| Category | Q1 2026 Status | Significance |
| Cumulative Regulatory Approvals | 440+ | Demonstrates global quality compliance |
| Cumulative Contract Value | USD 21.4 Billion | Long-term revenue visibility |
| ADC Modality Readiness | Commercial Scale | Expansion into high-growth drug classes |
| EcoVadis Sustainability Rating | Platinum | Top 1% of companies globally |
Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected. […]
Danaher Acquisition of Masimo Completed in $9.9B Diagnostics Mega-Deal
Danaher Corporation has finalized its acquisition of Masimo Corporation, establishing the pulse oximetry and patient monitoring provider as a stand-alone operating company within its Diagnostics […]
AstraZeneca Advances Oral GLP-1 RA Elecoglipron Asset into Phase III Programme Following Robust Phase IIb Results
AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to […]
Future Outlook: Sustaining Momentum
Looking ahead, the company is maintaining its 2026 guidance. The integration of CDO services (Internal Link), such as master cell bank production and vector construction, is expected to provide a “one-stop” solution for emerging biotech firms.
With the Samsung Biologics Q1 2026 Results setting a high bar, the focus for the remainder of the year will be on the “Bio Campus II” development and further diversifying the manufacturing network to meet regional supply needs.
By combining operational consistency with aggressive global expansion, Samsung Biologics continues to cement its position as the world’s leading CDMO.
